The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer

Craig Blum, Amanda Graham, Matt Yousefzadeh, Jessica Shrout, Katie Benjamin, Murli Krishna, Raza Hoda, Rana Hoda, David J. Cole, Elizabeth Garrett-Mayer, Carolyn Reed, Michael Wallace, Michael Mitas

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Colorectal cancer (CRC) is the second most frequent cause of cancer-related death in the United States. To determine whether certain molecular markers might be prognostic for survival, we measured by quantitative real-time RT-PCR the expression levels of 15 previously studied genes that are known to be up-regulated or down-regulated in the progression of epithelial cancers. The tumor samples were extracted from formalin-fixed paraffin-embedded primary tissues derived from patients with Stage II CRC who developed disease recurrence within two years (n=10), or were disease-free for at least 4 years (n=12). We were able to determine, by AUC curve analysis, that the ratio of microtubule associated protein 7 (Map7)/B2M was predictive of outcome in our sample set. Further, using Kaplan-Meier survival analysis, we observed significantly different curves as a function of marker positivity for the Map7/B2M (p=0.0001; HR= 11) expression ratio. This suggests that the expression ratio of Map7/B2M may serve as a valuable prognostic marker in patients with Stage II colon cancer, and potentially guide therapeutic decision making.

Original languageEnglish (US)
Pages (from-to)579-584
Number of pages6
JournalInternational journal of oncology
Volume33
Issue number3
DOIs
StatePublished - Sep 1 2008

    Fingerprint

Keywords

  • Colon cancer
  • Map7/B2M

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Blum, C., Graham, A., Yousefzadeh, M., Shrout, J., Benjamin, K., Krishna, M., Hoda, R., Hoda, R., Cole, D. J., Garrett-Mayer, E., Reed, C., Wallace, M., & Mitas, M. (2008). The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. International journal of oncology, 33(3), 579-584. https://doi.org/10.3892/ijo_00000043